Xiaohongshu shifts investment focus from beauty toward AI
TMTPost reports that Xiaohongshu has largely paused beauty-sector investing while accelerating AI-related deals, including a reported $1 billion Series A investment in Moonshot AI and three rounds of backing for AI e-paper company Yuexingtong. The article contrasts this shift with L’Oréal China’s continued industrial investment in beauty and technology companies, including a completed investment in recombinant mussel mucin developer Baiyin Biotechnology. It argues that capital in Chinese consumer technology is increasingly favoring companies with technical differentiation over growth based mainly on social-media exposure.
Xiaohongshu’s reported pivot from beauty investments to AI and hardware shows a major consumer platform redirecting capital toward frontier technology, while L’Oréal continues deploying funds across beauty supply chains and emerging technologies.
(本文作者为 看见美业,钛媒体经授权发布)
文 | 看见美业,作者 | 此间少年,编辑 | 卢旭成
“欧莱雅在寻找创新机会时,会重点挖掘消费者未被满足的需求与潜在市场空间,再匹配能够承接这些需求的前沿技术,在需求与技术的交叉点上完成布局。”欧莱雅CEO Nicolas Hieronimus表示。
落地到现实则是,日前欧莱雅中国旗下上海美次方投资有限公司,完成对深圳市“潜在独角兽企业”、深耕重组贻贝粘蛋白赛道的深圳柏垠生物科技有限公司的投资。工商信息显示,美次方对柏垠生物持股比例为7.133109%,对应注册资本认缴出资额13.6209万元,该金额并非实际投资总额。
除柏垠生物外,今年以来,欧莱雅通过旗下美次方,以及出资设立的凯辉创美未来、天图美丽领航等多支产业基金,先后完成对多家企业的投资:全周期头皮护理解决方案提供商可氏利夫、AI具身理疗机器人企业德壹医疗、再生医美材料企业摩漾生物、功效型底妆品牌蒂洛薇、氢分子抗衰新材料技术创新平台奇麟正维。其中,凯辉创美未来投资蒂洛薇的当月,蒂洛薇便登上抖音彩妆类目TOP1。
#Xiaohongshu#L’Oréal China#Shanghai Meicifang Investment#Baiyin Biotechnology#Moonshot AI#Yuexingtong#ByteDance#Kuaishou#TILOVY#Moyo Biotechnology